MedWatch Alert: FDA Requires Safety Labeling Changes For Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due To Potential Increased Risk Of Rare But Serious Eye Condition: FDA Safety Communication
The FDA is requiring GLP-1 drug labels to warn of a potential increased risk of rare NAION, which can cause sudden, painless vision loss.
